Baseline Patient Characteristics
| Characteristic | Data |
|---|---|
| Patients receiving 177Lu-PSMA RLT | 60 |
| 2 cycles | 23 |
| 3 cycles | 2 |
| ≥4 cycles | 35 |
| ECOG 0 | 19 |
| ECOG 1 | 34 |
| ECOG 2 | 7 |
| Age (y) | 72 (67–76) |
| PSA (ng/mL) | 132.3 (29.2–267.6) |
| LDH (U/L) | 252.5 (215.8–316.8) |
| AP (U/L) | 118.5 (78.0–211.8) |
| Hb (g/dL) | 11.5 (10.3–12.6) |
| Prior systemic therapies for mCRPC, n = 60 (%) | |
| Docetaxel | 44 (73) |
| Cabazitaxel | 12 (20) |
| Abiraterone | 46 (77) |
| Enzalutamide | 40 (67) |
| 223Ra | 12 (20) |
| Previous chemotherapy | 44 (73) |
| Site of metastasis, n = 60 | |
| Lymph node, overall | 49 |
| Lymph node, N1+/M1a | 5 |
| Bone, overall | 54 |
| Bone, M1b, without visceral metastases | 38 |
| Visceral, overall, M1c | 19 |
| Liver | 3 |
| Lung | 11 |
| Adrenal | 7 |
PSA = prostate-specific antigen; LDH = lactate dehydrogenase; AP = alkaline phosphatase; Hb = hemoglobin.
Qualitative data are number and percentage; continuous data are median and interquartile range.